Story perspectives

Study Questions Beta-Blocker Efficacy for Heart Attack Patients

9/6/2025

Summary

Story summary

The REBOOT trial with over 8,500 heart attack patients in Spain and Italy found no significant benefits of beta-blockers for those with preserved or mildly reduced heart function.
A substudy revealed women may face higher hospitalization risks and mortality when prescribed beta-blockers, especially at higher doses.
Dr. Borja Ibáñez called for a personalized approach to post-heart attack treatment, questioning beta-blocker efficacy.
Current guidelines still recommend beta-blockers, indicating a potential shift in clinical practice.
Future studies are needed to confirm these sex-specific results and improve treatment protocols for heart attack survivors.

1 of 1

Story summary

The REBOOT trial with over 8,500 heart attack patients in Spain and Italy found no significant benefits of beta-blockers for those with preserved or mildly reduced heart function.
A substudy revealed women may face higher hospitalization risks and mortality when prescribed beta-blockers, especially at higher doses.
Dr. Borja Ibáñez called for a personalized approach to post-heart attack treatment, questioning beta-blocker efficacy.
Current guidelines still recommend beta-blockers, indicating a potential shift in clinical practice.
Future studies are needed to confirm these sex-specific results and improve treatment protocols for heart attack survivors.